Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase I/II Two Center Safety and Tolerability Study

NCT03274076 is registered in ClinicalTrials.gov with University of Michigan as lead sponsor.

NCT NCT03274076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03274076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Phase I/II Two Center Safety and Tolerability Study
Lead sponsor
University of Michigan
Phase
Phase 1/2
Overall status
Completed
Start date
September 25, 2017
Completion date
November 15, 2019
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma, systemic sclerosis